** Adds ORCD is set for strong growth over the next three years as new management continues to execute the turnaround strategy well ** Co leveraging core strengths in key active pharma ingredients (APIs)-like anti-microbials such as Cephalosporin, ** Estimates 35%+ compound annual growth rate (CAGR) in earnings before interest, taxes, depreciation and...
NSE:ORCHPHARMA Direct on Long for 400% return. yearly breakout and retest done.
Positional Stock ORCHPHARMA (Orchid Pharma Ltd) looks good above 524 SL 475 Targets 570-600-625-650-700-750 holding period 6 months Pros- There is huge buying in the stock by FIIs & DIIs Stock has taken reversal and now seems like it is in uptrend Stock has raised 400 crore through QIP Cons Stock is trading at 2.94 times its book value Company has low...
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs Product Portfolio The Co has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular...
VOLUME HIGH RSI BULLISH CANDLE BULLISH